Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (October 2025)
24 slides from Defence Therapeutics Inc Class A's investor presentation, October 2025
Slide 1: Investor Presentation
Investor Presentation Biopharmaceutical Innovations for Future Generations CSE: DTC | FSE: DTC | OTCQB: DTCFF Q4 2025
Slide 2: Forward Looking Statements
Investor Presentation | Defence Therapeutics Forward Looking Statements DEFENCE THERAPEUTICS This presentation contains “forward-looking information” within the meaning of Defence’s short operating history; the possibility that Defence may never receive applicable securities laws in Canada, includin
Slide 3: Shaping the Future of Cancer Treatment with Smarter Drug Delivery
3 CANCER THERAPEUTICS Shaping the Future of Cancer Treatment with Smarter Drug Delivery Enhancing the power of ADCs and radiopharma to transform cancer care. 3
Slide 4: Our Vision and Strategies for Success
Theurapeutics DefenceTherapeutics Our Vision Strategies for Success Presentation | |Defence Investor Presentation Defence Therapeutics is creating therapies that are Partner with drug companies to improve antibody stronger, safer, and more precise –delivering impact for delivered drugs Investor pati
Slide 5: Management and Board Members
Investor Presentation | Defence Therapeutics Management and Board Members Arnab De Sebastien Plouffe Chief Financial Officer, Corporate Secretary CEO, Founder & Director CPA, CMGA, CMA, MBA, with more than 30 years Financial expert and entrepreneur with 30+ years of experience in finance, business opt
Slide 6: The Highlights
Investor Presentation | Defence Therapeutics THE HIGHLIGHTS Defence Therapeutics ● Publicly traded biotech firm based in Montreal, Canada, with an attractive capital structure and long-term investors. ● Worldwide extensive patent portfolio covering the Accum® platform technology; 8 granted US patents
Slide 7: Product Pipeline in Development
Investor Presentation | Defence Therapeutics Valuable Project Product Pipeline in Development Traction With a highly flexible Accum® platform and 100% IP ownership, Defence Therapeutics has an impactful group of cancer therapies in development. Emerging scientific data and market insights are driving
Slide 8: The Accum +ADC Program
8 CANCER THERAPEUTICS The Accum +ADC Program:® Expanding patient access and market opportunities for ADCs 8
Slide 9: Problem for Antibody-delivered Drugs
Investor Presentation | Defence Therapeutics Problem for Antibody-delivered Drugs Antibody conjugated ! drugs efficiently ‘target’ cells, but are inefficient Endosome intracellular navigators that often fail to hit the Cargo (biologics) ‘bullseye’ Dose 100x Entrapment ADCs must be delivered ! Endocyto
Slide 10: The Solution: Accum
Investor Presentation | Defence Therapeutics ® The Solution: Accum Defence Therapeutics’ Innovative Drug Delivery Platform ! Accum®-labelled biologics escape endosomes Endosome entrapment and degradation - enhancing their intracellular Cargo (biologics) “Accum®ulation” Dose 10x. Entrapment ! Endocyt
Slide 11: Our Solution: Accum
Investor Presentation | Defence Therapeutics ® Our Solution: Accum Defence Therapeutics’ Innovative Drug Delivery Platform Accum® Molecule Endosome Nucleus Escape tag Beacon ! Adding Accum® to an Antibody-conjugated drug will: Engineered molecular ‘tag’ that can be added to a any biologic drug •Redu
Slide 12: DEFN-101: Accum Enhanced On-Market ADC
Investor Presentation | Defence Therapeutics DEFN-101: Accum Enhanced On-Market ADC ADC vs Cell line 1 ADC vs Cell line 2 % Cell survival % Cell survival ADC ADC +Accum® +Accum® Concentration Concentration ! Data confirms, Accum® dramatically enhances potency of multiple ADCs and multiple cancer cell
Slide 13: Confirmed In Vivo PoC for ADC+Accum
Presentation|| Defence Theurapeutics Therapeutics Confirmed In Vivo PoC for ADC+Accum® Experiment demonstrating head to head superiority vs ADC alone Presentation ADC Investor Investor ADC ADC 0.5mg/kg ADC @ 0.5mg/kg Non-effective dose ACCUM-ADC 0.5mg/kg Effective dose 13 ! RESULT : Accum® makes an i
Slide 14: Validation of Accum with a novel ADC
Theurapeutics Therapeutics Validation of Accum® with a novel ADC Defence Investor Presentation | |Defence Tumor Volume (mm3) ADC-X (1 mg/kg) + Accum (1 mg/kg) Days ! RESULT : Accum may revive ADCs abandoned in development, unlocking new markets 14
Slide 15: Accum has transformational potential for antibody delivered drugs
Investor Presentation | Defence Therapeutics Accum® has transformational potential for antibody delivered drugs Current advised doses for ADCs= 3.6mg/kg Plasma Free [Toxin] = ~7 nM ~40–50% of ADC-treated patients What if Extrapolated dose of ACCUM- ADCs= 0.72mg/kg Plasma Free [Toxin] =~1.4 nM ~0 % o
Slide 16: The Power of Accum
The Power of Accum® Investor Presentation | Defence Therapeutics ! ! On-market ADCs are approved as second-line therapies only Potent ADCs could be suitable first-line therapies, due to the dose-limiting toxicities expanding patient access and market opportunities Kadcyla Enhertu Trastuzumab $2.2B $3
Slide 17: Advancing ADC's beyond today's limits
Investor Presentation | Defence Therapeutics Advancing ADC’s beyond today’s limits Novel IP for endosome escape Works across all ADCs tested Greater drug availability Striking results in vivo models 17 confidential
Slide 18: The Radio-Immuno-Conjugates Programs
18 CANCER THERAPEUTICS The Radio-Immuno-Conjugates Programs: Indications: Solid Tumors 18
Slide 19: Radiopharmaceuticals Programs
Investor Presentation | Defence Therapeutics Radiopharmaceuticals Programs 1) Accum®/AccuTOX® - Actinium 225 • 100% owned by Defence • Collaboration with the Canadian Nuclear Laboratories to perform the studies • Development of targeted radiopharmaceuticals therapy using Accum® & AccuTOX® with Actin
Slide 20: The AccuTOX Program
20 CANCER THERAPEUTICS The AccuTOX ® Program: Ready for Phase I in Canada, FDA clearance Study May Proceed in the USA Indication: Melanoma 20
Slide 21: AccuTOX
Investor Presentation | Defence Therapeutics AccuTOX® Dimers of Accum® have a therapeutic activity by themselves without being conjugated to any biologics + Accum® Accum® AccuTOX® 21 Bikorimana JP, et al., J Transl Med. 2024 Jun 3;22(1):532.
Slide 22: AccuTOX-001 Halts Tumor Development When Combined with ICI
Investor Presentation | Defence Therapeutics AccuTOX®-001 Halts Tumor Development When Combined with Immune-Checkpoint Inhibitors (ICI) Synergistic effect against ICI-resistant Tumors 22 Bikorimana JP, et al., J Transl Med. 2024 Jun 3;22(1):532.
Slide 23: Connect
Connect (514) 947 - 2272 info@defencetherapeutics.com www.defencetherapeutics.com Laboratories and Offices: 7171 Frederick Banting Montreal, QC, H4S 1Z9
Slide 24: Bibliography Articles
Investor Presentation | Defence Therapeutics Bibliography Articles 1. Lacasse V et al., Mol Ther Methods Clin Dev. 2020 Sep 1;19:99-119. 2. Paquette M et al., Bioconjug Chem. 2018 Apr 18;29(4):1352-1363. 3. Beaudoin S et al., Mol Pharm. 2016 Jun 6;13(6):1915-26. 4. El-Kadiry AE et al., Molecules. 20
Defence Therapeutics — Investor Presentation (October 2025) on 6ix